** Shares of cancer drug developer Lantern Pharma rise ~15% to $3.63 premarket
** LTRN says the U.S. Food and Drug Administration has granted "fast track" designation to its experimental drug to treat a type of breast cancer called triple negative breast cancer (TNBC)
** The drug, LP-184, showed preclinical efficacy in treating TNBC - LTRN
** FDA's "fast track" status expedites the review of medicines to treat serious conditions
** As of last close, stock has fallen 26.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。